Fortrea Reschedules Release of First Quarter 2024 Financial Results and Conference Call
DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO),...
Clinical Trial
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature...
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
- Stockholders’ equity significantly surpasses the $2.5 million minimum required by Nasdaq - Company is to seek Nasdaq’s formal confirmation...
Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting...
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing...
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical...
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick...
EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting
Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the...
ImPact Biotech Presents Preliminary Phase 3 Results from ENLIGHTED Study of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer
Encouraging response rate shown; CR in 67% (6/9) of patients who completed the Induction Treatment Phase Padeliporfin VTP generally well-tolerated,...
Nanomerics Wins the United Kingdom King’s Award for Enterprise Innovation 2024
Nanomerics Ltd., a private speciality pharmaceutical company today announced that it had been awarded the prestigious King's Award for Enterprise...
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
GOTHENBURG, SWEDEN / ACCESSWIRE / May 6, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 6, 2024 - IRLAB Therapeutics...
Angle PLC Announces New Commercial Agreement with Large Pharma
ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies GUILDFORD, SURREY / ACCESSWIRE...
PreveCeutical Announces Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - May 2, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or...
Rymedi Announces Strategic Partnership to Improve Patient Experience and Advance Patient Registry Supported by Web3 and DeSci
GREENVILLE, SC / ACCESSWIRE / May 2, 2024 / Rymedi and Precision Genetics, two leading pioneers in healthcare technology solutions, proudly announce...
Rymedi and Precision Genetics Announce Strategic Partnership to Advance Precision Medicine and Healthcare Innovation
GREENVILLE, SC / ACCESSWIRE / May 2, 2024 / Rymedi and Precision Genetics, two leading pioneers in healthcare technology solutions,...
Establishment Labs Notes Presentation of 4-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2024
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,...
New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged
-- Reprieve Cardiovascular Partners with Leading Heart Failure Researchers and Truveta to Analyze Real-World Heart Failure Patient Data to Highlight...
Zomedica Strengthens Market Position with New Patents Issued for its TRUFORMA(R) Diagnostic Platform
Intellectual property portfolio now includes 188 Patents and 131 Trademarks providing robust protection for the Company's product platforms ANN ARBOR,...
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for...
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab...